Literature DB >> 2830815

Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis.

L B Heifets1, P J Lindholm-Levy, M D Iseman.   

Abstract

The minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) of rifabutine (ansamycin LM427, spiropiperidyl rifamycin) against rifampin-susceptible and rifampin-resistant strains of Mycobacterium tuberculosis were determined. The MICs for 17 rifampin-susceptible strains were low, falling in a narrow range of 0.06 microgram/ml or less when determined by either the agar-dilution method (in 7H10 or 7H11 agar) or in 7H12 broth (radiometrically or by sampling and colony-forming units [CFU/ml] determination). The MICs of rifabutine for 21 rifampin-resistant strains were much higher, ranging from 0.25 to 16.0 micrograms/ml. The MBCs of rifabutine were 0.125 or 0.25 microgram/ml for rifampin-susceptible strains, and were 4.0 and 32.0 micrograms/ml for two tested rifampin-resistant strains. The MIC/MBC ratio was 1:4 for rifampin-susceptible strains.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2830815     DOI: 10.1164/ajrccm/137.3.719

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

Review 1.  Bacterial challenges and evolving antibacterial drug strategy.

Authors:  B Watt; J G Collee
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

2.  Rapid determination of rifampin resistance in clinical isolates of Mycobacterium tuberculosis by real-time PCR.

Authors:  Tanil Kocagoz; Zeynep Saribas; Alpaslan Alp
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

Review 3.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

4.  MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

5.  Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis.

Authors:  L Heifets; P Lindholm-Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 6.  Treatment and prevention of multidrug-resistant tuberculosis.

Authors:  I Bastian; R Colebunders
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

Review 7.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

8.  Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis.

Authors:  D Jabès; C Della Bruna; R Rossi; P Olliaro
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.

Authors:  Zenda L Berrada; Shou-Yean Grace Lin; Timothy C Rodwell; Duylinh Nguyen; Gisela F Schecter; Lucy Pham; J Michael Janda; Wael Elmaraachli; Antonino Catanzaro; Edward Desmond
Journal:  Diagn Microbiol Infect Dis       Date:  2016-02-03       Impact factor: 2.803

Review 10.  Clinical pharmacokinetics of rifabutin.

Authors:  M H Skinner; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.